Archives of Cardiovascular Diseases最新文献

{"title":"Addendum to “Scientific statement from the French neurovascular and cardiac societies for improved detection of atrial fibrillation after ischaemic stroke and transient ischaemic attack” [Arch. Cardiovasc. Dis. 117 (2024) 542–557]","authors":"Nicolas Gaillard , Jean-Claude Deharo , Laurent Suissa , Pascal Defaye , Igor Sibon , Christophe Leclercq , Sonia Alamowitch , Céline Guidoux , Ariel Cohen , French Neurovascular Society, French Society of Cardiology","doi":"10.1016/j.acvd.2024.10.001","DOIUrl":"10.1016/j.acvd.2024.10.001","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Page 140"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143162999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous circulatory assistance in an interventional cardiology centre without on-site cardiac surgery","authors":"Ibrahim Hatoum ,&nbsp;Paul Luporsi ,&nbsp;Philippe Riccini ,&nbsp;Frédéric Collart ,&nbsp;Ziad Boueri","doi":"10.1016/j.acvd.2024.10.331","DOIUrl":"10.1016/j.acvd.2024.10.331","url":null,"abstract":"<div><h3>Background</h3><div>Percutaneous extracorporeal membrane oxygenation (ECMO) has been developed thanks to the progress in the field of cannulation, but still justifies the presence of an on-site cardiac resuscitation department. Corsica is a French island without an on-site cardiac surgery department.</div></div><div><h3>Aim</h3><div>To evaluate the percutaneous ECMO programme in Corsica.</div></div><div><h3>Methods</h3><div>All patients who received ECMO at the Bastia Hospital Centre between 01 January 2016 and 30 April 2022 were included.</div></div><div><h3>Results</h3><div>ECMO was implanted in 39 patients. The mean age was 52.7<!--> <!-->years, with male predominance (84.6%). The majority of veno-arterial ECMOs were placed in the coronary angiography laboratory, whereas venovenous ECMOs were preferentially placed in the medical intensive care unit. Twenty patients (51.3%) were medically transferred to other referral centres after canulation. Percutaneous vascular cannulation was performed with ultrasound guidance in all cases (100%), and was successfully performed without immediate complications in all patients except two (who presented an immediate complication during cannulation), which is similar to large trials, despite the absence of on-site cardiac surgery. The use of ultrasound guidance (and sometimes fluoroscopy guidance) during cannulation and the experience of the medical team facilitated control over correct positioning of the cannulas and decreased implantation failure, without the need for a surgical approach.</div></div><div><h3>Conclusions</h3><div>Percutaneous ECMO by trained interventional cardiologists without a surgical approach appears to be safe. Widespread use of percutaneous cannulation without cardiac surgery would increase survival for some patients who are far from these centres.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Pages 101-105"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter commenting on the article entitled “Cardiogenic shock and infection: A lethal combination” by Cherbi et al.","authors":"Sravani Modumudi,&nbsp;Vanessa Rodriguez,&nbsp;Laura Calderon Suarez","doi":"10.1016/j.acvd.2024.08.010","DOIUrl":"10.1016/j.acvd.2024.08.010","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Pages 136-137"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","authors":"Joe-Elie Salem ,&nbsp;Stephane Ederhy ,&nbsp;Lisa Belin ,&nbsp;Noel Zahr ,&nbsp;Florence Tubach ,&nbsp;Adrien Procureur ,&nbsp;Yves Allenbach ,&nbsp;Michelle Rosenzwjag ,&nbsp;Marie Bretagne","doi":"10.1016/j.acvd.2024.12.005","DOIUrl":"10.1016/j.acvd.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitor (ICI)-induced myocarditis is a life-threatening adverse drug reaction. Abatacept (a CTLA-4-immunoglobulin fusion protein) has been proposed as a compassionate-use treatment for ICI myocarditis (in combination with corticosteroids and ruxolitinib) but no clinical trial has yet been performed. The abatacept dose can be adjusted using real-time assessment of its target, the CD86 receptor occupancy on circulating monocytes (CD86RO).</div></div><div><h3>Methods</h3><div>The ACHLYS trial is an ongoing dose-finding, Phase II, randomized, double-blind trial in which three different abatacept doses are being tested, aiming to reach CD86RO<!--> <!-->≥<!--> <!-->80% after the first dose and sustainably during the first 3 weeks of ICI myocarditis treatment (primary outcome). Adult patients with cancer presenting severe or corticosteroid-resistant ICI myocarditis have been included. ICI are withheld after inclusion and for the study duration. Abatacept is administered by intravenous injection on Days 1, 5<!--> <!-->±<!--> <!-->2 and 14<!--> <!-->±<!--> <!-->2 at 10, 20 or 25<!--> <!-->mg/kg depending on the randomization arm (<em>n</em> <!-->=<!--> <!-->7 per arm) with concomitant ruxolitinib and corticosteroids. After evaluation of the primary outcome on Day 21, complementary injections of abatacept (for<!--> <!-->≤<!--> <!-->3 months) and a ruxolitinib/corticosteroids weaning strategy are standardized depending on criteria evaluating resolution of ICI myocarditis severity (troponin T level and clinical assessment). Secondary objectives compare immunological, myocardial and muscular proxies of treatment response between randomization arms, and cancer progression-free and overall survivals up to 1 year.</div></div><div><h3>Conclusion</h3><div>The ACHLYS trial will define the most appropriate starting dose of abatacept to treat life-threatening ICI myocarditis, in combination with ruxolitinib and corticosteroids.</div></div><div><h3>Clinicaltrials.gov</h3><div><span><span>NCT05195645</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Pages 106-115"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convergent procedure for long-standing persistent atrial fibrillation in heart failure with reduced ejection fraction","authors":"Frédéric A. Sebag ,&nbsp;Konstantinos Zannis ,&nbsp;Manel Miled ,&nbsp;Justine Durand ,&nbsp;Pierre Jorrot ,&nbsp;Olivier Villejoubert ,&nbsp;Nicolas Mignot ,&nbsp;Jean-Marc Darondel ,&nbsp;Baptiste Courty ,&nbsp;Edouard Simeon ,&nbsp;Eric Bergoend ,&nbsp;Randall Lee ,&nbsp;Nicolas Lellouche","doi":"10.1016/j.acvd.2024.10.333","DOIUrl":"10.1016/j.acvd.2024.10.333","url":null,"abstract":"<div><h3>Background</h3><div>Catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction is associated with a significant reduction in morbimortality. The convergent procedure is a valid ablation option for the treatment of long-standing persistent atrial fibrillation.</div></div><div><h3>Aim</h3><div>To describe the outcomes of patients with heart failure with reduced ejection fraction and long-standing persistent atrial fibrillation who underwent the convergent procedure.</div></div><div><h3>Methods</h3><div>We studied consecutive patients included in two French centres between 2009 and 2020. Primary endpoint was freedom from any atrial arrhythmia assessed on 24-hour Holter electrocardiogram at 3, 6 and 12 months after the procedure. Left ventricular ejection fraction was assessed on transthoracic echocardiography before and 1 year after the procedure. All patients had at least 12 months of follow-up.</div></div><div><h3>Results</h3><div>Forty-three patients were included (86% were men). Baseline left ventricular ejection fraction was 38<!--> <!-->±<!--> <!-->10.5% and indexed left atrial volume was 50<!--> <!-->±<!--> <!-->27<!--> <!-->mL/m². Among the study population, 34 patients (79%) were free from atrial fibrillation/tachycardia at the end of follow-up. No periprocedural death occurred. We observed two groin haematomas and four mild pericardial effusions. At 12-month follow-up, 21 patients (49%) were still on antiarrhythmic drug therapy, and a reduction in antiarrhythmic drug dosage was achieved in 10 patients (23%). The absolute median improvement in left ventricular ejection fraction was 8% at 12 months (<em>P</em> <!-->=<!--> <!-->0.003).</div></div><div><h3>Conclusions</h3><div>The convergent procedure has been shown to be effective and safe for patients with patients with heart failure with reduced ejection fraction and long-standing persistent atrial fibrillation, with significant left ventricular function improvement.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Pages 116-122"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinician viewpoint on the 2024 European guidelines on the management of patients with atrial fibrillation","authors":"Laurent Fauchier ,&nbsp;Jean Claude Deharo ,&nbsp;Frederic Sacher ,&nbsp;Ariel Cohen","doi":"10.1016/j.acvd.2024.12.003","DOIUrl":"10.1016/j.acvd.2024.12.003","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 2","pages":"Pages 81-84"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specific and non-specific prognostic scores in patients with out-of-hospital cardiac arrest caused by ST-segment elevation myocardial infarction: A comparative study.","authors":"Vincent Pham, Tahar Ghannam, Olivier Varenne, Alain Cariou, Florence Dumas, Donia Mafi, Fabien Picard","doi":"10.1016/j.acvd.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.acvd.2024.12.011","url":null,"abstract":"<p><strong>Background: </strong>Patients resuscitated after out-of-hospital cardiac arrest (OHCA) have a poor prognosis, with high death rates. Multiple scoring systems have been developed to predict survival in all-comers with OHCA. Acute coronary syndromes and ST-segment elevation myocardial infarction (STEMI) are the primary causes of OHCA. Recently, a specific prognostic score (Tran risk model) was developed for patients with STEMI-related OHCA.</p><p><strong>Aim: </strong>To compare the accuracy of established non-STEMI-specific prognostic scores (OHCA, modified CAHP and NULL-PLEASE) with the Tran risk model in predicting in-hospital death among patients with STEMI-related OHCA.</p><p><strong>Methods: </strong>This was an observational single-centre study including 315 consecutive patients treated for STEMI-related OHCA. The OHCA score was calculated for 310 patients (98.4%), the NULL-PLEASE and modified CAHP (mCAHP) scores were calculated for 308 patients (97.8%) and the Tran risk model score was calculated for 306 patients (97.1%). A C-statistic analysis was performed to determine score performance.</p><p><strong>Results: </strong>The area under the curve (AUC) for the Tran risk model was 0.75 (95% confidence interval [CI] 0.69-0.79). The AUCs for the OHCA, mCAHP and NULL-PLEASE scores were 0.74 (95% CI 0.69-0.80), 0.74 (95% CI 0.69-0.80) and 0.76 (95% CI 0.71-0.82), respectively. There was no significant difference in AUCs between the Tran risk model and the mCAHP score (P=0.95), the NULL-PLEASE score (P=0.42) or the OHCA score (P=0.93). Similarly, no significant difference was observed between the mCAHP, NULL-PLEASE and OHCA scores. Predictors of death were no-flow duration, diabetes, blood lactate, femoral access and age>75 years.</p><p><strong>Conclusions: </strong>The OHCA, NULL-PLEASE and mCAHP scores and the Tran risk model showed moderate to good performance in predicting in-hospital death in patients with STEMI-related OHCA. No differences in accuracy were found between non-STEMI-specific scores and the Tran risk model developed for patients with STEMI-related OHCA.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments.","authors":"Simon Travers, Joachim Alexandre, Lauren A Baldassarre, Joe Elie Salem, Mariana Mirabel","doi":"10.1016/j.acvd.2024.12.012","DOIUrl":"https://doi.org/10.1016/j.acvd.2024.12.012","url":null,"abstract":"<p><p>Diagnosing cancer therapy-related cardiovascular toxicities may be a challenge. The interplay between cancer and cardiovascular diseases, beyond shared cardiovascular and cancer risk factors, and the increasingly convoluted cancer therapy schemes have complicated cardio-oncology. Biomarkers used in cardio-oncology include serum, imaging and rhythm modalities to ensure proper diagnosis and prognostic stratification of cardiovascular toxicities. For now, troponin and natriuretic peptides, multimodal cardiovascular imaging (led by transthoracic echocardiography combined with cardiac magnetic resonance or computed tomography angiography) and electrocardiography (12-lead or Holter monitor) are cornerstones in cardio-oncology. However, the imputability of cancer therapies is sometimes difficult to assess, and more refined biomarkers are currently being studied to increase diagnostic accuracy. Advances reside partly in pathophysiology-based serum biomarkers, improved cardiovascular imaging through new technical developments and remote monitoring for rhythm disorders. A multiparametric omics approach, enhanced by deep-learning techniques, should open a new era for biomarkers in cardio-oncology in the years to come.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early and late bleeding events according to Valve Academic Research Consortium 3 criteria following transcatheter aortic valve implantation.","authors":"Maxime Nolf, Dominique Boulmier, Guillaume Leurent, Jacques Tomasi, Florent Le Bars, Abdelkader Bakhti, Sam Sharobeem, Léo Lemarchand, Gwenaelle Sost, Marielle Le Guellec, Hervé Le Breton, Vincent Auffret","doi":"10.1016/j.acvd.2024.12.009","DOIUrl":"https://doi.org/10.1016/j.acvd.2024.12.009","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation may be associated with significant haemorrhagic complications.</p><p><strong>Aims: </strong>To evaluate the timing, incidence, predictors and clinical impact of bleeding events after transcatheter aortic valve implantation, according to the updated Valve Academic Research Consortium (VARC)-3 criteria, compared with the VARC-2 criteria.</p><p><strong>Methods: </strong>A retrospective observational study involving 487 consecutive patients who underwent transcatheter aortic valve implantation between July 2017 and May 2019 was performed. Bleeding events were classified according to the VARC-2 and VARC-3 definitions.</p><p><strong>Results: </strong>Bleeding events occurred in 17.6% of patients, with early bleeding (in-hospital) in 12.5% and late bleeding (occurring after discharge) in 6.1%. The primary vascular access site was the most common source of early bleeding, whereas gastrointestinal bleeding was predominant in late events. Significant predictors of early VARC-3-defined bleeding included active cancer, previous implantable cardioverter-defibrillator, history of mitral valve surgery, a non-transfemoral approach and occurrence of an in-hospital major vascular complication or new-onset atrial fibrillation. Late bleeding was independently associated with a history of myocardial infarction and treatment with vitamin K antagonists at discharge. Early bleeding events were not associated with increased late all-cause mortality. No significant difference was observed based on the VARC-2 and VARC-3 bleeding definitions.</p><p><strong>Conclusions: </strong>Bleeding events occurred in one sixth of patients undergoing transcatheter aortic valve implantation without significant difference in their incidence between the VARC-2 and VARC-3 classifications. Early bleeding events were not associated with poorer long-term survival, regardless of the classification used. Larger studies with greater statistical power, including more contemporary patients, are needed to confirm these findings.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning to detect recent recreational drug use in intensive cardiac care units.","authors":"Nathan El Bèze, Kenza Hamzi, Patrick Henry, Antonin Trimaille, Amine El Ouahidi, Cyril Zakine, Olivier Nallet, Clément Delmas, Victor Aboyans, Marc Goralski, Franck Albert, Eric Bonnefoy-Cudraz, Thomas Bochaton, Guillaume Schurtz, Pascal Lim, Antoine Lequipar, Trecy Gonçalves, Emmanuel Gall, Thibaut Pommier, Léo Lemarchand, Christophe Meune, Sonia Azzakani, Claire Bouleti, Jonas Amar, Jean-Guillaume Dillinger, P Gabriel Steg, Eric Vicaut, Solenn Toupin, Théo Pezel","doi":"10.1016/j.acvd.2024.12.010","DOIUrl":"https://doi.org/10.1016/j.acvd.2024.12.010","url":null,"abstract":"<p><strong>Background: </strong>Although recreational drug use is a strong risk factor for acute cardiovascular events, systematic testing is currently not performed in patients admitted to intensive cardiac care units, with a risk of underdetection. To address this issue, machine learning methods could assist in the detection of recreational drug use.</p><p><strong>Aims: </strong>To investigate the accuracy of a machine learning model using clinical, biological and echocardiographic data for detecting recreational drug use in patients admitted to intensive cardiac care units.</p><p><strong>Methods: </strong>From 07 to 22 April 2021, systematic screening for all traditional recreational drugs (cannabis, opioids, cocaine, amphetamines, 3,4-methylenedioxymethamphetamine) was performed by urinary testing in all consecutive patients admitted to intensive cardiac care units in 39 French centres. The primary outcome was recreational drug detection by urinary testing. The framework involved automated variable selection by eXtreme Gradient Boosting (XGBoost) and model building with multiple algorithms, using 31 centres as the derivation cohort and eight other centres as the validation cohort.</p><p><strong>Results: </strong>Among the 1499 patients undergoing urinary testing for drugs (mean age 63±15 years; 70% male), 161 (11%) tested positive (cannabis: 9.1%; opioids: 2.1%; cocaine: 1.7%; amphetamines: 0.7%; 3,4-methylenedioxymethamphetamine: 0.6%). Of these, only 57% had reported drug use. Using nine variables, the best machine learning model (random forest) showed good performance in the derivation cohort (area under the receiver operating characteristic curve=0.82) and in the validation cohort (area under the receiver operating characteristic curve=0.76).</p><p><strong>Conclusions: </strong>In a large intensive cardiac care unit cohort, a comprehensive machine learning model exhibited good performance in detecting recreational drug use, and provided valuable insights into the relationships between clinical variables and drug use through explainable machine learning techniques.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}